Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-002241-11 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Naldemedine | Experimental | Participants received 0.2 mg naldemedine orally once daily for 12 weeks. |
|
| Placebo | Placebo Comparator | Participants received matching placebo orally once daily for 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Naldemedine | Drug | Naldemedine 0.2 mg tablet taken orally once a day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. An SBM was defined as a bowel movement that occurred without the use of rescue laxative therapy during the 24 hours prior to the BM. A responder was defined as a participant having 9 or more positive response weeks out of the 12-week Treatment Period and 3 positive response weeks out of last 4 weeks of the 12-week Treatment Period. A positive response week was defined as ≥ 3 SBMs per week and an increase from baseline of ≥ 1 SBM per week for that week. If a participant had less than 4 days of diary entries for a week, that week was treated as a "non-response" week. Any participant with insufficient primary endpoint data (data for less than 9 out of 12 weeks of the Treatment Period or less than 3 out of the last 4 weeks of the 12-week Treatment Period) was treated as a non-responder. | 12-week treatment period |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. An SBM was defined as a bowel movement that occurred without the use of a rescue laxative therapy during the 24 hours prior to the BM. Baseline was defined as the 14 days in the screening period prior to study drug administration. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shionogi Clinical Trials Administrator Clinical Support Help Line | Shionogi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shionogi Research Site | Birmingham | Alabama | United States | |||
| Shionogi Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34377150 | Derived | Hale ME, Wild JE, Yamada T, Yokota T, Tack J, Andresen V, Drewes AM. Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives. Ther Adv Gastroenterol. 2021 Jul 31;14:17562848211032320. doi: 10.1177/17562848211032320. eCollection 2021. | |
| 34295186 |
Not provided
Not provided
Participants were randomized in a 1:1 ratio to 0.2 mg of naldemedine or placebo. Participants were stratified based on their documented opioid use (average total daily dose (TDD) during the 14-consecutive-day qualifying period) as follows:
This study was conducted at 68 sites in North America and Europe, including Austria, Czech Republic, Germany, Poland, Spain, United Kingdom, and the United States.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Naldemedine | Participants received 0.2 mg naldemedine orally once daily for 12 weeks. |
| FG001 | Placebo | Participants received placebo orally once daily for 12 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo tablet taken orally once a day |
|
| Baseline and the last 2 weeks of the treatment period (Weeks 11 and 12 for participants who completed 12 weeks of treatment) |
| Change From Baseline to Week 1 in the Number of Spontaneous Bowel Movements Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. An SBM was defined as a bowel movement that occurred without the use of a rescue laxative therapy during the 24 hours prior to the BM. Baseline was defined as the 14 days in the screening period prior to study drug administration. | Baseline and Week 1 |
| Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. A complete spontaneous bowel movement (CSBM) was defined as an SBM which was accompanied by the feeling of complete evacuation. | Baseline and the last 2 weeks of the treatment period (Weeks 11 and 12 for participants who completed 12 weeks of treatment) |
| Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements With No Straining Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. The severity of straining with each bowel movement was assessed on the following scale: 0=no straining, 1=mild straining, 2=moderate straining, 3=severe straining, 4=very severe straining. SBMs without straining were defined as SBMs with a straining score of 0. | Baseline and the last 2 weeks of the treatment period (Weeks 11 and 12 for participants who completed 12 weeks of treatment) |
| Phoenix |
| Arizona |
| United States |
| Shionogi Research Site | Fresno | California | United States |
| Shionogi Research Site | Long Beach | California | United States |
| Shionogi Research Site | National City | California | United States |
| Shionogi Research Site | North Hollywood | California | United States |
| Shionogi Research Site | Oceanside | California | United States |
| Shionogi Research Site | Golden | Colorado | United States |
| Shionogi Research Site | Miami | Florida | United States |
| Shionogi Research Site | Miami Springs | Florida | United States |
| Shionogi Research Site | Orlando | Florida | United States |
| Shionogi Research Site | Sarasota | Florida | United States |
| Shionogi Research Site | West Palm Beach | Florida | United States |
| Shionogi Research Site | Winter Park | Florida | United States |
| Shionogi Research Site | Marietta | Georgia | United States |
| Shionogi Research Site | Shreveport | Louisiana | United States |
| Shionogi Research Site | Caro | Michigan | United States |
| Shionogi Research Site | Flint | Michigan | United States |
| Shionogi Research Site | Hazelwood | Missouri | United States |
| Shionogi Research Site | Las Vegas | Nevada | United States |
| Shionogi Research Site | Belvidere | New Jersey | United States |
| Shionogi Research Site | East Brunswick | New Jersey | United States |
| Shionogi Research Site | Albuquerque | New Mexico | United States |
| Shionogi Research Site | Great Neck | New York | United States |
| Shionogi Research Site | Hollis | New York | United States |
| Shionogi Research Site | New Windsor | New York | United States |
| Shionogi Research Site | Winston-Salem | North Carolina | United States |
| Shionogi Research Site | Cincinnati | Ohio | United States |
| Shionogi Research Site | Oklahoma City | Oklahoma | United States |
| Shionogi Research Site | Medford | Oregon | United States |
| Shionogi Research Site | West Reading | Pennsylvania | United States |
| Shionogi Research Site | Chattanooga | Tennessee | United States |
| Shionogi Research Site | Arlington | Texas | United States |
| Shionogi Research Site | Austin | Texas | United States |
| Shionogi Research Site | Dallas | Texas | United States |
| Shionogi Research Site | Houston | Texas | United States |
| Shionogi Research Site | San Antonio | Texas | United States |
| Shionogi Research Site | Sankt Pölten | Austria |
| Shionogi Research Site | Vienna | Austria |
| Shionogi Research Site | Hradec Králové | Czechia |
| Shionogi Research Site | Liberec | Czechia |
| Shionogi Research Site | Pardubice | Czechia |
| Shionogi Research Site | Prague | Czechia |
| Shionogi Research Site | Vysoké Mýto | Czechia |
| Shionogi Research Site | Berlin | Germany |
| Shionogi Research Site | Eichstätt | Germany |
| Shionogi Research Site | Frankfurt am Main | Germany |
| Shionogi Research Site | Bialystok | Poland |
| Shionogi Research Site | Bydgoszcz | Poland |
| Shionogi Research Site | Czeladź | Poland |
| Shionogi Research Site | Gorzów Wielkopolski | Poland |
| Shionogi Research Site | Warsaw | Poland |
| Shionogi Research Site | Alicante | Spain |
| Shionogi Research Site | Cadiz | Spain |
| Shionogi Research Site | Madrid | Spain |
| Shionogi Research Site | Belfast | United Kingdom |
| Shionogi Research Site | Bexhill-on-Sea East Sussex | United Kingdom |
| Shionogi Research Site | Crownhill Plymouth | United Kingdom |
| Shionogi Research Site | Fowey Cornwall | United Kingdom |
| Shionogi Research Site | Liskeard Cornwall | United Kingdom |
| Shionogi Research Site | London | United Kingdom |
| Shionogi Research Site | Penzance Cornwall | United Kingdom |
| Shionogi Research Site | Saint Austell Cornwall | United Kingdom |
| Shionogi Research Site | Soham Ely Cambs | United Kingdom |
| Shionogi Research Site | Tomairt | United Kingdom |
| Camilleri M, Hale M, Morlion B, Tack J, Webster L, Wild J. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. J Pain Res. 2021 Jul 16;14:2179-2189. doi: 10.2147/JPR.S282738. eCollection 2021. |
| 33965574 | Derived | Tack J, Camilleri M, Hale M, Morlion B, Nalamachu S, Webster L, Wild J. Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation. Clin Gastroenterol Hepatol. 2022 Apr;20(4):855-863. doi: 10.1016/j.cgh.2021.05.004. Epub 2021 Aug 5. |
| 32280263 | Derived | Webster LR, Hale ME, Yamada T, Wild JE. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy. J Pain Res. 2020 Mar 24;13:605-612. doi: 10.2147/JPR.S237833. eCollection 2020. |
| 32086791 | Derived | Wild J, Webster L, Yamada T, Hale M. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients >/= 65 Years of Age. Drugs Aging. 2020 Apr;37(4):271-279. doi: 10.1007/s40266-020-00753-2. |
| 31145214 | Derived | Wild J, Yamada T, Arjona Ferreira JC, Hale M. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials. Pain. 2019 Oct;160(10):2358-2364. doi: 10.1097/j.pain.0000000000001629. |
| 28576452 | Derived | Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555-564. doi: 10.1016/S2468-1253(17)30105-X. Epub 2017 May 30. |
| Received Treatment |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
The intent-to-treat population included all randomized participants; one participant was excluded from each arm due to enrollment at 2 different sites simultaneously.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Naldemedine | Participants received 0.2 mg naldemedine orally once daily for 12 weeks. |
| BG001 | Placebo | Participants received placebo orally once daily for 12 weeks. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Age, Customized | Number | participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| ||||||||||||||||
| Stratification by Opioid Dose | Dose of opioid was calculated using maintenance and breakthrough morphine equivalent dose. If any participants were treated with < 30 mg, the participants were counted in '30-100 mg'. | Number | participants |
| |||||||||||||||
| Spontaneous Bowel Movements per Week | Mean | Standard Deviation | spontaneous bowel movements |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. An SBM was defined as a bowel movement that occurred without the use of rescue laxative therapy during the 24 hours prior to the BM. A responder was defined as a participant having 9 or more positive response weeks out of the 12-week Treatment Period and 3 positive response weeks out of last 4 weeks of the 12-week Treatment Period. A positive response week was defined as ≥ 3 SBMs per week and an increase from baseline of ≥ 1 SBM per week for that week. If a participant had less than 4 days of diary entries for a week, that week was treated as a "non-response" week. Any participant with insufficient primary endpoint data (data for less than 9 out of 12 weeks of the Treatment Period or less than 3 out of the last 4 weeks of the 12-week Treatment Period) was treated as a non-responder. | Intent-to-treat population | Posted | Number | 95% Confidence Interval | percentage of participants | 12-week treatment period |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. An SBM was defined as a bowel movement that occurred without the use of a rescue laxative therapy during the 24 hours prior to the BM. Baseline was defined as the 14 days in the screening period prior to study drug administration. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | spontaneous bowel movements / week | Baseline and the last 2 weeks of the treatment period (Weeks 11 and 12 for participants who completed 12 weeks of treatment) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 1 in the Number of Spontaneous Bowel Movements Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. An SBM was defined as a bowel movement that occurred without the use of a rescue laxative therapy during the 24 hours prior to the BM. Baseline was defined as the 14 days in the screening period prior to study drug administration. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | spontaneous bowel movements / week | Baseline and Week 1 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. A complete spontaneous bowel movement (CSBM) was defined as an SBM which was accompanied by the feeling of complete evacuation. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | complete spontaneous BMs / week | Baseline and the last 2 weeks of the treatment period (Weeks 11 and 12 for participants who completed 12 weeks of treatment) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements With No Straining Per Week | A bowel movement and constipation assessment (BMCA) was completed by participants every day during the screening and treatment periods to record information about bowel movements (BMs) and constipation. The severity of straining with each bowel movement was assessed on the following scale: 0=no straining, 1=mild straining, 2=moderate straining, 3=severe straining, 4=very severe straining. SBMs without straining were defined as SBMs with a straining score of 0. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | SBMs with no straining / week | Baseline and the last 2 weeks of the treatment period (Weeks 11 and 12 for participants who completed 12 weeks of treatment) |
|
|
From the first dose of study drug to 28 days after the last dose of study drug (16 weeks).
The Safety Population included all randomized participants who received at least 1 dose of study drug. One participant was excluded from each arm due to simultaneous enrollment at 2 different sites.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Naldemedine | Participants received 0.2 mg naldemedine orally once daily for 12 weeks. | 14 | 271 | 29 | 271 | ||
| EG001 | Placebo | Participants received placebo orally once daily for 12 weeks. | 5 | 272 | 11 | 272 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Appendicitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Transient ischaemic attack | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Supraventricular tachycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Ventricular extrasystoles | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Deep vein thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Patent ductus arteriosus | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Device failure | General disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Ligament sprain | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal pain | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
|
The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Shionogi Clinical Trials Administrator | Shionogi Inc. | 800-849-9707 | 1454 | shionogiclintrials-admin@shionogi.co.jp |
| ID | Term |
|---|---|
| D000079689 | Opioid-Induced Constipation |
| ID | Term |
|---|---|
| D003248 | Constipation |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000620491 | naldemedine |
Not provided
Not provided
Not provided
| ≥ 40 to < 65 years |
|
| ≥ 65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Black or African American |
|
| Native Hawaiian or Other Pacific Islander |
|
| White |
|
| > 100 mg |
|
|
|
|
|
|
|
|
|